India Sickle Cell Anaemia Market is predicted to reach USD 0.90 billion at a CAGR of 14.68% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global India Sickle Cell Anaemia Market”.

The Sickle Cell Anaemia Market is estimated to register a CAGR of 14.68% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the India sickle cell anaemia market— Cipla Ltd (India), United Biotech Pvt Ltd. (India), Neon (India), Novartis AG (Switzerland), Taj Pharmaceuticals Limited. (India), Celon Labs (India), Salius Pharma Pvt. Ltd (India), Pfizer Inc (US), Emmaus Medical, Inc (US), and Teva Pharmaceutical Industries Ltd (Israel).

India Sickle Cell Anaemia Market Highlights

The India sickle cell anaemia market is accounted for to register a CAGR of 14.68% during the forecast period and is estimated to reach USD 0.90 billion by 2032.

The rising prevalence of sickle cell anemia in India has resulted in an increased demand for drug treatments to manage the disease and its complications. Because of the large number of sickle cell anemia patients in India, particularly in tribal and rural communities, there is an urgent need for effective pharmaceutical interventions to alleviate symptoms and improve patients' quality for life. As per the Ministry of Tribal Affairs, Government of India, sickle cell disease (SCD), a hereditary disorder, is prevalent within India's tribal communities estimating that around one out of every 86 births among scheduled tribes (STs) are affected by SCD. In July 2023, the Ministry of Health and Family Welfare reported that nearly 278 districts of tribal areas were majorly affected in India. Thus, the increasing prevalence of sickle cell disease, coupled with drug approval and initiatives for production in order to meet consumer demand, is fostering the growth of the Indian sickle cell anemia market.

Growing government support and policies associated with sickle cell anaemia in India and increased prevalence of sickle cell among India increases the demand for drug treatment are propelling market growth. However, high cost of bone marrow transplant and side effects associated with drug treatment are expected to hamper the growth of the India market. Nevertheless, the Indian government is forming partnerships with Indian manufacturers to produce affordable sickle cell disease medications is projected to create lucrative opportunities for market players.

Access full details on India Sickle Cell Anaemia Research Report  

Segment Analysis

The India sickle cell anaemia market has been segmented based on type and diagnosis & treatment type.

On the basis of type, the market is segmented into over the Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia. The over the sickle cell anemia (SS) segment was attributed to holding the largest market share of over 63.23% in 2022 revenue as estimated by MRFR analysts. This is due to the increasing disease awareness, rise in complications associated with sickle cell anemia.

Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product launches.

On the basis of the diagnosis & treatment type, the market is segmented into diagnosis & treatment type. Furter, the diagnosis segment is further segmented into instruments and reagents and kits. Furthermore, the treatment segment is further bifurcated into pharmacotherapy, blood transfusion, and bone marrow transplant. The pharmacotherapy segment is projected to have the largest market share during the forecast period. This is due to prevalence of sickle beta-zero thalassemia, a severe form of thalassemia and rising healthcare expenditure, and advancement in diagnosis and treatment.

Key Findings of the Study

• The India sickle cell anaemia market is expected to reach USD 0.90 billion by 2032, at a CAGR of 14.68% during the forecast period.


• Based on type, the Sickle Cell Anemia (SS) segment was attributed to holding the largest market in 2022, with an approximate market share of around 63.23%


• Cipla Ltd (India), United Biotech Pvt Ltd. (India), Neon (India), Novartis AG (Switzerland), Taj Pharmaceuticals Limited. (India), Celon Labs (India), Salius Pharma Pvt. Ltd (India), Pfizer Inc (US), Emmaus Medical, Inc (US), and Teva Pharmaceutical Industries Ltd (Israel) are the key market players.